Investigation of urinary extracellular vesicles as novel and safe therapeutics for autosomal recessive polycystic kidney disease
尿细胞外囊泡作为常染色体隐性遗传性多囊肾病的新型安全疗法的研究
基本信息
- 批准号:10750704
- 负责人:
- 金额:$ 46.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-04 至 2025-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAffectAgeAmniotic FluidAutosomal Dominant Polycystic KidneyAutosomal Recessive Polycystic KidneyBindingBiodistributionBiologicalBirthCell CommunicationCellsCessation of lifeCharacteristicsChildhoodClinical TrialsDevelopmentDiseaseDisease ProgressionDoseDrug KineticsDrug Side EffectsEnd stage renal failureFDA approvedFetal LungFetusGeneticHalf-LifeHepatotoxicityHomeHourHumanIn VitroInjectionsIntravenousInvestigationKidneyKidney DiseasesKidney FailureKidney TransplantationLifeLive BirthMeasuresMembraneMessenger RNAModelingMothersMusMutateMutationNephrologyNewborn InfantOligohydramniosPKHD1 geneParentsPathway interactionsPatientsPharmaceutical PreparationsPhase I Clinical TrialsPilot ProjectsPolycystic Kidney DiseasesProliferatingPropertyProteinsPulmonary Valve InsufficiencyRNARattusReceptor Protein-Tyrosine KinasesRenal functionResearchRespirationSafetySourceTestingTherapeuticTherapeutic EffectToxic effectTranslatingTreatment EfficacyTyrosine Kinase InhibitorUrineVasopressin ReceptorWorkautosomebiomaterial compatibilitybody cavitycongenital hepatic fibrosiscpk mousedesigndisease phenotypeeffective therapyexosomeextracellular vesiclesfetalgene productgene therapyin uteroin vivoinhibitorinsightkidney celllung developmentmouse modelmultidisciplinarynanomedicinenanoparticleneonatenovelnovel strategiesnovel therapeutic interventionnovel therapeuticspatient populationpediatric patientspregnantprotein expressionpulmonary hypoplasiapupsmall moleculetargeted treatmenttherapeutic nanoparticlestherapy developmenttherapy outcometolvaptanurinary
项目摘要
ABSTRACT
Autosomal recessive polycystic kidney disease (ARPKD) is a leading cause of kidney failure in childhood and is
caused primarily by mutations in the PKHD1 gene as well as mutations in CYS1. Although ARPKD patients
progress to end stage kidney disease at varying ages, 20-30% of ARPKD patients have severe disease which
results in death 24-48 hours after birth. Despite the tremendous unmet need, limited progress has been made
for ARPKD treatment and no FDA-approved therapies are available for ARPKD patients. Although tolvaptan, a
small molecule drug that was approved in 2018 for autosomal dominant PKD which mostly affects adults, is
currently under phase I clinical trials for ARPKD, tolvaptan is not kidney-targeted and results in off-target effects.
Additionally, tolvaptan’s long-term efficacy, tolerability, and developmental consequences in a primarily pediatric
ARPKD patient population and its ability to enhance survival in neonates with severe ARPKD is unknown. Thus,
new therapeutic strategies that can address both safety and efficacy in ARPKD are urgently needed. To that
end, the purpose of this proposal is to examine the potential of urinary extracellular vesicles (uEVs) as a novel
and safe therapy for ARPKD. EVs, also known as exosomes, are secreted, membrane-bound, biological
nanoparticles that facilitate cell-to-cell communication and contain RNA and protein cargo characteristic to their
parent cell. We propose uEVs for ARPKD therapy for several reasons: uEVs are 1) inherently biocompatible
which is critically important when developing therapies for pediatric patients, 2) carry fibrocystin and cystin, the
gene products of PKHD1 and CYS1 which are mutated in ARPKD, respectively, 3) have been found to home to
the kidneys and transfer functional proteins to induce a therapeutic outcome in kidney disease, and 4) obtaining
high quantities uEV from urine, which is normally discarded, is feasible, noninvasive, and cheap. We hypothesize
that uEVs derived from non-disease sources are a safe therapy that can be used to deliver and supplement
functional proteins including fibrocystin and cystin that are defective in ARPKD to inhibit disease progression. To
test our hypothesis, we will first characterize the nanoparticle properties of uEVs and evaluate uEV fibrocystin
and cystin protein and mRNA cargo, cell internalization, and therapeutic effects in renal cells in vitro (Aim 1).
Next, we will administer uEVs intravenously in slowly progressing and severe ARPKD murine models and
evaluate the pharmacokinetic properties, therapeutic efficacy, and safety in vivo (Aim 2.1). Finally, given most
human ARPKD leads to death in utero or in newborns shortly after birth, we will deliver uEVs in utero in pregnant
mice and evaluate the ability to extend survival in severe ARPKD upon fetal delivery (Aim 2.2). Through our
multidisciplinary, investigative team of nanomedicine and pediatric nephrology, we are well-equipped and fully
committed to successfully carry out this work that is much needed in ARPKD therapy.
抽象的
常染色体隐性多囊肾病 (ARPKD) 是儿童期肾衰竭的主要原因,
主要由 PKHD1 基因突变和 CYS1 突变引起。尽管 ARPKD 患者
在不同年龄进展为终末期肾病,20-30%的 ARPKD 患者患有严重疾病,
导致出生后 24-48 小时内死亡。尽管存在巨大的未满足需求,但取得的进展有限
ARPKD 治疗目前尚无 FDA 批准的治疗方法可用于 ARPKD 患者。尽管托伐普坦
2018 年批准用于治疗主要影响成人的常染色体显性多囊肾病的小分子药物是
目前正在进行针对 ARPKD 的 I 期临床试验,托伐普坦不是肾脏靶向的,会导致脱靶效应。
此外,托伐普坦在主要儿科患者中的长期疗效、耐受性和发育后果
ARPKD 患者群体及其提高严重 ARPKD 新生儿生存率的能力尚不清楚。因此,
迫切需要能够解决 ARPKD 安全性和有效性的新治疗策略。对此
最后,该提案的目的是检查尿液细胞外囊泡(uEV)作为一种新型药物的潜力
ARPKD 的安全治疗。 EV,也称为外泌体,是分泌的、膜结合的、生物性的
纳米粒子促进细胞间通讯并含有其特有的RNA和蛋白质货物
父细胞。我们建议 uEV 用于 ARPKD 治疗有几个原因:uEV 1) 本质上具有生物相容性
这在为儿科患者开发治疗方法时至关重要,2) 携带纤维囊肿蛋白和胱氨酸,
PKHD1 和 CYS1 的基因产物分别在 ARPKD 中发生突变,3) 已被发现
肾脏并转移功能蛋白以诱导肾脏疾病的治疗结果,以及 4) 获得
从通常被丢弃的尿液中提取大量 uEV 是可行的、非侵入性的且便宜。我们假设
来自非疾病来源的 uEV 是一种安全的疗法,可用于传递和补充
ARPKD 中存在缺陷的功能蛋白(包括纤维囊肿蛋白和胱氨酸)可抑制疾病进展。到
为了检验我们的假设,我们将首先表征 uEV 的纳米颗粒特性并评估 uEV 纤维囊肿蛋白
胱氨酸蛋白和 mRNA 货物、细胞内化以及体外肾细胞的治疗效果(目标 1)。
接下来,我们将在进展缓慢和严重的 ARPKD 小鼠模型中静脉注射 uEV,
评估体内药代动力学特性、治疗功效和安全性(目标 2.1)。最后,给出最
人类 ARPKD 会导致子宫内或新生儿出生后不久死亡,我们将在怀孕期间在子宫内输送 uEV
小鼠并评估在胎儿分娩时延长严重 ARPKD 患者生存的能力(目标 2.2)。通过我们的
纳米医学和小儿肾脏病学多学科、研究团队,设备齐全,设施齐全
致力于成功开展 ARPKD 治疗急需的这项工作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eun Ji Chung其他文献
Eun Ji Chung的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eun Ji Chung', 18)}}的其他基金
Multimodal Peptide Amphiphile Micelles for Atherosclerosis
用于治疗动脉粥样硬化的多模式肽两亲胶束
- 批准号:
9321402 - 财政年份:2015
- 资助金额:
$ 46.57万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 46.57万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 46.57万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 46.57万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 46.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 46.57万 - 项目类别:
Standard Grant
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 46.57万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 46.57万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 46.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 46.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 46.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)